Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevalence of Homologous Recombination Repair (HRR) Gene Mutations in Patients With Metastatic Castration-resistant Prostate Cancer in Latin America: PROSPECT Study.

NCT04962880 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04962880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04962880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevalence of Homologous Recombination Repair (HRR) Gene Mutations in Patients With Metastatic Castration-resistant Prostate Cancer in Latin America: PROSPECT Study.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
April 21, 2021
Completion date
April 8, 2022
Enrollment
388 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer